Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 3 selected

Type

Guidance programme 6 selected

Guidance programme

Showing 1 to 10 of 1010

TitleReference numberPublishedLast updated
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA1021
Bevacizumab gamma for treating wet age-related macular degenerationTA1022
Eplontersen for treating hereditary transthyretin-related amyloidosisTA1020
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosisTA1018
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and overTA1019
Elafibranor for previously treated primary biliary cholangitisTA1016
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1015
Avapritinib for treating advanced systemic mastocytosisTA1012

Results per page

  1. 10
  2. 25
  3. 50
  4. All